INVO Fertility, Inc. - 8-K Filing

INVO Fertility reports Q3 2026 revenue growth of 26% to $2.2M alongside seventh consecutive quarter of positive Clinic-Level Adjusted EBITDA. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $IVF

Read the full article at SEC EDGAR

Part of the story INVO Fertility, Inc. - 10-Q Filing (2 articles)

More Regulatory news